Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Sirona Biochem Corp V.SBM

Alternate Symbol(s):  SRBCF

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.


TSXV:SBM - Post by User

Comment by biorunon Jan 29, 2024 5:56pm
108 Views
Post# 35851501

RE:RE:RE:New Press Release - Sirona Biochem Announces Loan

RE:RE:RE:New Press Release - Sirona Biochem Announces LoanAnyone who lends this kind of money has to know they have a pretty much 100% chance of getting paid back. 

And he is making 12% plus another 450,000 bonus shares. The risk payment (interest) doesn't match the reward because it is him in the privileged information seat. He can also demand the money be paid back on priority notice in the event something is about to sour overall..

Again, I would argue "follow the motivation of the money". He is essentially augmenting his salary but if anyone here really knows what is around the corner it is him.

So I would argue, let's let greed and capitalism play out here. I would be willing to bet there is plenty in the bush here, otherwise he would have done this before and lent this kind of money on any of the previous rounds.



<< Previous
Bullboard Posts
Next >>